Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION (INCY)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 10/20 10:00:00 pm
114.19 USD   -0.07%
10/12 INCYTE : to Report Third Quarter Financial Results
10/06 NASDAQ 100 MOVE : Cost, incy
10/06 INCYTE : and Cancer Support Community Delaware Announce the Establis..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
116.6(c) 115.64(c) 115.14(c) 114.27(c) 114.19(c) Last
1 821 407 1 799 649 1 687 853 1 838 242 1 564 941 Volume
+2.00% -0.82% -0.43% -0.76% -0.07% Change
More quotes
Financials ($)
Sales 2017 1 471 M
EBIT 2017 -79,4 M
Net income 2017 -174 M
Finance 2017 394 M
Yield 2017 -
Sales 2018 1 680 M
EBIT 2018 105 M
Net income 2018 89,0 M
Finance 2018 923 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 319,50
EV / Sales2017 16,1x
EV / Sales2018 13,8x
Capitalization 24 054 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology.Its product, Jakafi, a JAK1 and JAK2 inhibitor, is... 
Sector
Biotechnology & Medical Research
Calendar
10/31 | 12:00pmEarnings Release
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
10/19 INCYTE : and Cancer Support Community Delaware Announce the Establishment of the..
10/17 IBD Announces First Annual Biotech Innovator Awards
10/12 INCYTE : to Report Third Quarter Financial Results
10/07 NEXTERA ENERGY : Natixis Asset Management Has Lifted Its Incyte Corp. (INCY) Hol..
10/06 NASDAQ 100 MOVERS : Cost, incy
10/06 INCYTE : and Cancer Support Community Delaware Announce the Establishment of the..
09/21 INCYTE : Health
09/21 INCYTE : Merus Intellectual Property Portfolio Expands with Two New Patents For ..
09/19 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. To Its Board of Directors
09/18 ALEXION PHARMACEUTICALS, INC. (NASDA : ALXN) Files An 8-K Departure of Directors..
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03:56aFDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant  
02:48aComing soon. Book No 2! ? #entrepreneurship #smallbusiness #incy  
01:01aFDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant  
10/20One drug's prospects has propelled Incyte to a giddy $26 billion valuation
2
10/20$INCY catching a bid after hours. Up 4 points. No news on the wire yet. 
More tweets
Qtime:73
News from SeekingAlpha
10/19 INCYTE AND FLEXUS : The Grappling Continues
10/19 USPTO rejects Incyte's challenge to Concert Pharma patent; shares up 5%
10/18 The Math Behind the Gilead's Recent Merger
10/18 NETFLIX PORTFOLIO : Final Performance Update
10/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 13, 2017
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 149 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC33.89%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.208.84%10 522
SEATTLE GENETICS, INC.21.30%9 134